76532-33-7

Usage

Uses

Used in Agricultural Industry:
Methyl-(naphthalen-2-ylmethyl)azanium is used as an intermediate in the preparation of detoxification inhibitors of the crucifer phytoalexin Brassinin. It serves as a potential fungicide against Leptosphaeria maculans, a plant pathogen that causes blackleg and stem canker diseases in cruciferous crops. By inhibiting the detoxification process of Brassinin, methyl-(naphthalen-2-ylmethyl)azanium helps to enhance the effectiveness of fungicides and protect crops from diseases.

InChI:InChI=1/C12H13N/c1-13-9-10-6-7-11-4-2-3-5-12(11)8-10/h2-8,13H,9H2,1H3

Upstream product

• 120350-92-7 methyl-[2]naphthylmethylen-amine 
• 66-99-9 β-naphthaldehyde 
• 74-89-5 methylamine 
• 939-26-4 2-bromomethylnaphthyl bromide 
• 5470-96-2 quinoline 2-carbaldehyde 
• 2506-41-4 1-chloromethylnaphthalene 
• 3815-22-3 N-methyl-2-naphthalenecarboxamide 
• 125660-64-2 N-methyl-1-(naphthalene-2-yl)methanimine 

Downstream Products

• 104257-80-9 N-<3-(1-cyclohexenyl)-2-propinyl>-N-methyl-2-naphthalinmethanamin 
• 104257-88-7 (E)-N-<3-(1-cyclohexenyl)-2-propenyl>-N-methyl-2-naphthalinmethanamin 
• 1262999-67-6 2-(methyl(naphthalen-2-ylmethyl)amino)benzaldehyde 
• 1486473-57-7 N-benzyl-N-(naphthalen-2-ylmethyl)-2-vinylaniline 
• 98978-29-1 3--1-phenyl-1-propanone 
• 1443159-49-6 5-(biphenyl-4-ylmethyl)-N-methyl-N-(naphthalen-2-ylmethyl)-1H-tetrazole-1-carboxamide 
• 1443159-53-2 5-(biphenyl-4-ylmethyl)-N-methyl-N-(naphthalen-2-ylmethyl)-2H-tetrazole-2-carboxamide 
• 98977-54-9 (E)-N-methyl-N-(3-phenyl-2-propenyl)-2-naphthalenemethanamine 
• 98978-36-0 3--1-phenyl-1-propanol 

Relevant academic research and scientific papers

Identification of impurities in the production of terbinafine hydrochloride

The purity of the parent substance of (E)-N-(6,6-dimethylhept-2-en-4-ynyl)- N-methylnaphth-1-ylmethylamine (terbinafine) is evaluated via TLC identification of the main impurities appearing during its synthesis via alkylation of N-methylnaphth-1-ylmethylamine with 1-chloro-6,6-dimethyl-2-hept-2-en-4-yne The possible formation of impurities including N-methyl-N,N-di(methylnaphth-1-yl) amine, N-methylnaphth-1-ylmethylamine, N-methylnaphth-2-ylmethylamine, (E)-N-(6,6-dimethylhept-2-en-4-ynyl)-N-methylnaphth-1-ylmethylamine, (Z)-N-(6,6-dimethylhept-2-en-4-ynyl)-N-methylnaphth-1-ylmethylamine, (E)-N-(6,6-dimethylhept-2-en-4-ynyl)-N-methylnaphth-2-ylmethylamine, and (Z)-N-(6,6-dimethylhept-2-en-4-ynyl)-N-methylnaphth-2-ylmethylamine was confirmed by means of countersynthesis.

Highly enantioselective synthesis of tetrahydroquinolines via cobalt(II)-catalyzed tandem 1,5-hydride transfer/cyclization

A chiral catalyst prepared from N,N′-dioxide and Co(BF 4)2·6H2O was applied in the asymmetric hydride transfer initiated cyclization reaction, giving optically active tetrahydroquinolines in good yields with high enantioselectivities under mild reaction conditions. Meanwhile, in light of the absolute configuration of the product, a possible working model was proposed to explain the origin of the activation and asymmetric induction.

PHARMACEUTICAL COMPOUNDS

The invention provides a compound which is a pyrimidine of formula (I): The compounds are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

TACHYKININ RECEPTOR ANTAGONISTS

The present invention relates to selective NK-1 receptor antagonists of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins.

FAB I INHIBITORS

Compounds of the formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections.

HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY

In part, the present invention is directed to antibacterial compounds of formula (I) wherein A is a bicyclic heteroaryl ring or a tricyclic ring and R2 is an heterocyclic residue; L is a bond, or L is alkyl, alkenyl or cycloalkyl.

Tuning saccharide selectivity in modular fluorescent sensors

Five modular photoinduced electron-transfer (PET) sensors bearing two phenylboronic acid receptors with different fluorophores have been prepared. The sensors' interaction with saccharides was assessed via fluorescence spectroscopy. It was shown that monosaccharide selectivity is influenced by the choice of fluorescent moiety.

Antifungal amine derivatives and processing for producing the same

Novel amine derivatives having an excellent antimycotic effect represented by general formula (1) below and salts thereof are provided. [in the formula (1, R1represents a C1-5alkyl group which may be halogenated, R2represents 4-(1,1-dimethylalkyl)benzyl group, 4-(1-methyl-phenylethyl)benzyl group, 1-or 2-naphthylmethyl group, or a hydrocarbon group having 3,3-dimethyl-1-butynyl group or a phenyl group at its terminal and 1 to 3 double bonds; R3represents oxygen atom or a methylene group which may be substituted by a C1-4alkyl group; and R4represents 1-or 2 naphthyl group or a phenyl group which may be substituted.

Kinetic investigations provide additional evidence that an enzyme-like binding pocket is crucial for high enantioselectivity in the bis-cinchona alkaloid catalyzed asymmetric dihydroxylation of olefins

The Sharpless enantioselective dihydroxylation of terminal olefins by OsO4 using the catalytic chiral ligand (DHQD)2PYDZ (1) has been shown to follow Michaelis-Menten kinetics, demonstrating fast reversible formation of a complex of

Folate Antagonists. 18. Synthesis and Antimalarial Effects of N6-(Arylmethyl)-N6-methyl-2,4,6-pteridinetriamines and Related N6,N6-Disubstituted 2,4,6-Pteridinetriamines

N6-(Arylmethyl)-N6-methyl-2,4,6-pteridinetriamines (1-5) and related N6-substituted 2,4,6-pteridinetriamines (16-20) were obtained by the condensation of 6-chloro-2,4-pteridinediamine with methylarylmethanamine and other selected secondary amines.The requisite N-methylarylmethanamines (21-32) were prepared by the hydrogenation over Pt/C of the corresponding arylcarboxaldehyde in the presence of methanamine.Several of the N6-(arylmethyl)-N6-methyl-2,4,6-pteridinetriamines exhibited exceptional suppressive antimalarial activity against a drug-sensitive line of Plasmodium berghei in mice.N6-Methyl-N6-(1-naphthalenylmethyl)-2,4,6-pteridinetriamine (9), the most active of those compounds, was also shown to be curative at 3.16 mg/kg in a single oral dose against P. cynomolgi in the rhesus monkey.This compound was also shown to be effective against a chloroquine-resistant line of P. berghei in the mouse but showed cross-resistance to a pyrimethamine-resistant strain.Most of the 2,4,6-pteridinetriamines showed strong antibacterial action against Streptococcus faecalis and Staphylococcus aureus.